NCT03903094 is a clinical trial of Non-Interventional in Overactive Bladder (OAB), sponsored by Astellas Pharma Singapore Pte. Ltd..

Who is sponsoring NCT03903094?

NCT03903094 is sponsored by Astellas Pharma Singapore Pte. Ltd..

What drugs are being tested in NCT03903094?

Interventions in NCT03903094: Non-Interventional.

What condition does NCT03903094 study?

NCT03903094 studies Overactive Bladder (OAB).

Is NCT03903094 still recruiting?

NCT03903094 is currently completed. Last updated 31 October 2024.

Last reviewed 2024-10-31 · How we verify

NCT03903094

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic Burden

Completed Last updated 31 October 2024

What this trial tests

trial testing Non-Interventional in Overactive Bladder (OAB) in 6,295,279 participants. Completed in 6 May 2022.

Timeline

7 March 2019

Primary endpoint
6 May 2022

6 May 2022

Quick facts

Lead sponsor	Astellas Pharma Singapore Pte. Ltd.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	6,295,279
Start date	7 March 2019
Primary completion	6 May 2022
Estimated completion	6 May 2022
Sites	2 locations across Australia, South Korea

Drugs / interventions tested

Non-Interventional

Conditions studied

Overactive Bladder (OAB) — all drugs for Overactive Bladder (OAB) →

Sponsor

Astellas Pharma Singapore Pte. Ltd.

Who can join

65 and older, any sex, with Overactive Bladder (OAB). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Outpatients with at least one dispensing record of any medication will be included in the study. An index date will be assigned to each participant and prescription records for anticholinergics will be used in the study.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Reply to Beyond Anticholinergic Burden: An Integral Theory Perspective on Overactive Bladder - A Commentary on "A Retrospective Database Analysis of Anticholinergic Burden Among Older Patients With and Without Overactive Bladder in South Korea".
Lee KS, Cho J, Kang D, Ko KJ, et al · · 2026 · PMID 41942340 · DOI 10.5213/inj.2652006.003
A Retrospective Database Analysis of Anticholinergic Burden Among Older Patients With and Without Overactive Bladder in South Korea.
Lee KS, Cho J, Kang D, Ko KJ, et al · · 2025 · PMID 41077792 · DOI 10.5213/inj.2550112.056
A retrospective database analysis of anticholinergic burden among older patients with and without overactive bladder in South Korea
Lee K, Cho J, Park H, Kang D, et al · · 2024 · DOI 10.21203/rs.3.rs-4181851/v1

Verify or expand the search:

Other trials of Non-Interventional

Trials testing the same drug.

NCT06412029 — Understanding and Enhancing Health-Related Social Needs (HRSN) Screening Among Community Oncology Practices · enrolling by invitation
NCT05568459 — A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standa · active not recruiting
NCT06527508 — Construct Validity and Intra-Observer Reliability of the SDQ · completed
NCT05919511 — Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease · recruiting
NCT05510908 — Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC · completed

Other recruiting trials for Overactive Bladder (OAB)

Currently open trials in the same condition.

NCT07193407 — INOPASE - Performance and Safety Study of a Personalised SNM System · NA · recruiting
NCT07209397 — Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women · NA · recruiting
NCT07195656 — Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB) · NA · recruiting
NCT07025044 — Assessing the Genitourinary Microbiome of Women With Overactive Bladder Undergoing Onabotulinum Toxin Type A Intradetrus · recruiting
NCT07371000 — Early Detection of OAB and Elimination of Negative Impact on Quality of Life · NA · recruiting

Other Astellas Pharma Singapore Pte. Ltd. trials

Trials by the same sponsor.

NCT06734585 — Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell Transplant · completed
NCT06505746 — A Study of Real-world Treatment of Adults With Urothelial Cancer in South Korea and Saudi Arabia · completed
NCT04553029 — A Survey Evaluating Prevalence, Severity and Associated Factors in East Asian Women With Moderate-to-severe Menopause-re · completed
NCT03602508 — Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania · completed
NCT03572231 — A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03903094 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Astellas Pharma Singapore Pte. Ltd.
Last refreshed: 31 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03903094.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing